United Kingdom: Life Sciences, Biotechnology & Nanotechnology

ValiRx's subsidiary Cytolytix has received positive signals from the European Patent Office regarding patent protection for its polyleucine-based anti-cancer peptides, raising questions about why the company is publicly announcing these intellectual property developments. The strategic timing and nature of these announcements may reveal important insights about the company's approach to attracting investment and licensing partners in the competitive biotechnology sector.

Human papillomavirus vaccination has dramatically reduced cervical cancer rates in young women across the EU, but could the same approach work for HPV-positive oropharyngeal cancer, which has tripled in incidence among Scandinavian men over three decades? As gender-neutral vaccination programs roll out and immunotherapy strategies evolve, the landscape for treating and potentially preventing HPV-driven head and neck cancers is undergoing a fundamental transformation.

Women with BRCA1 or BRCA2 gene mutations depend on enhanced breast screening for early detection, but administrative gaps in the screening pathway can occur. This comprehensive guide empowers BRCA carriers with practical strategies to monitor their screening schedule, ask the right questions of healthcare providers, and confidently navigate potential administrative issues that could interrupt their care.

From Victorian engineering to modern AI, explore how David Kirkaldy's 1865 Universal Testing Machine and his pioneering data-driven approach laid the groundwork for today's materials informatics revolution. Discover how patent protection has evolved to protect innovations in computational materials science and machine learning applications.

Quantum sensing technology is revolutionizing healthcare diagnostics and treatment, with innovations ranging from brain function assessment devices to cancer detection platforms. As the quantum industry transitions from concept to reality, patent protection and strategic intellectual property management are becoming crucial for companies developing these transformative medical technologies.

The Advocate General has delivered a decisive opinion on whether a substance classified as an excipient in a marketing authorisation can be considered an active ingredient for Supplementary Protection Certificate eligibility purposes. This non-binding opinion addresses Halozyme's attempts to obtain SPC protection for a combination involving a substance designated as an excipient, with potentially far-reaching implications for pharmaceutical patent strategy and the relationship between regulatory classificat

The MHRA’s proposed rare disease therapies regulatory framework (“the Proposed Framework”) represents an ambitious attempt to redesign medicines regulation around the realities of rare disease development.

The MHRA has launched a consultation on proposed updates to the definition of gene therapy medicinal products (“GTMPs”) under the UK Human Medicines Regulations 2012 (“HMRs”).

As set out in the EPO’s recently-released Technology Dashboard 2025 (its annual summary of key figures and trends in patent activity), growth in the field of battery technologies continues unabated, with the number...